About Simulations Plus, Inc
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California. Address: 42505 Tenth Street West, Lancaster, CA, United States, 93534-7059
Simulations Plus, Inc News and around…
Latest news about Simulations Plus, Inc (SLP) common stock and company :
Simulations Plus (NASDAQ: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the Dispensary of Hope. Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.
Simulations Plus donates $25,000 to Dispensary of Hope, a national nonprofit devoted to delivering high-quality medication to underserved communities
Polen Capital, an investment management firm, published its “Polen U.S. Small Company Growth” third quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly return of 1.94% was delivered by the fund for the third quarter of 2021, outperforming its Russell 2000 Growth benchmark that delivered a -5.64% return for […]
Simulations Plus announced that Sharlene Evans, a proven leader, has joined the Company's Board of Directors replacing the retiring Dr. David Ralph.
Simulations Plus presented results from its QSP model NAFLDsym showing the impact of yo-yo dieting on placebo response rates in NASH clinical trials.
Simulations Plus announced the release of RENAsym version 1A, its novel QST software for predicting and investigating drug-induced kidney injury.
In trading on Wednesday, shares of Simulations Plus Inc (SLP) crossed above their 200 day moving average of $55.15, changing hands as high as $55.97 per share. Simulations Plus Inc shares are currently trading up about 1.6% on the day..
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When picking winners for the next decade plus, projections can only take you so far. These 10 stocks to buy sweeten the deal with dividends. The post 10 Long-term Stocks to Buy for the Next 15 Years appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Simulations Plus has released version 9.8.2 of its flagship GastroPlus PBBM/PBPK modeling program with essential new models, options, and workflows.
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company ...
View more earnings on SLPSee more from BenzingaClick here for options trades from BenzingaSelecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease TreatmentsAxcella To Test NASH Candidate In Long COVID Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Gainers Wallbox N.V. (NYSE: WBX) shares climbed 54.5% to $17.16. Uber and Wallbox N.V. disclosed a strategic partnership to ...
Simulations Plus announced a new FDA-funded grant award with the University of Connecticut to enhance mechanistic models for long-acting injectables.
SLP earnings call for the period ending August 31, 2021.
Gainers Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 10.73% to $208.6 during Monday's after-market session. The market value ...
Simulations Plus (SLP) delivered earnings and revenue surprises of -87.50% and 20.97%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Simulations Plus today reported financial results for the 4th quarter & full fiscal year 2021. Total FY21 revenue increased 12% to $46.5 million.
Companies Reporting Before The Bell • HNI (NYSE:HNI) is expected to report quarterly earnings at $0.43 per share on ...
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Simulations Plus, Inc...
Simulations Plus launched its University+ Program offering students & educators at accredited universities free 1-year access to the company software.
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap 600— Equal Weight ETF (EWSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $98.03 per unit.
The after-effects of pandemic-era policies will be with us for some time — with many supply chains still experiencing significant disruption. The worst of this “scarring” will heal. But the acceleration of tech adoption will be with us permanently.
Shareholders of Simulations Plus Inc (SLP) looking to boost their income beyond the stock's 0.6% annualized dividend yield can sell the November covered call at the $45 strike and collect the premium based on the 95 cents bid, which annualizes to an additional 23.9% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 24.5% annualized rate in the scenario where the stock is not called away. Any upside above $45 would be lost if the stock rises there and is called away, but SLP shares would have to climb 8.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 11% return from this trading level, in addition to any dividends collected before the stock was called.
Simulations Plus announced today that its Board of Directors has declared a cash dividend of $0.06 per share to be distributed on Nov. 1, 2021.
Simulations Plus announced today that it will report its 4th quarter and fiscal year 2021 results on Mon., Oct. 25, 2021, with a webcast at 5:00pm ET.
Virginia Woltosz, Director at Simulations Plus (NASDAQ:SLP), made a large insider sell on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Woltosz sold 20,000 shares of Simulations Plus at prices ranging from $38.32 to $38.78. The total transaction amounted to $770,788. Woltosz still owns a total of 4,396,483 shares of Simulations Plus worth, $174,232,621. Simulations Plus shares are trading up 0.4
Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 30.57% to $30.02 during Wednesday's after-market session. Today's trading ...
Simulations Plus announced a new grant award from the FDA to enhance the predictive power of the mechanistic TCAT model in its flagship GastroPlus.